Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mifepristone (RU 486): current knowledge and future prospects

J R Goldberg1, M G Plescia, G D Anastasio

  • 1Department of Family Practice, Carolinas Medical Center, Charlotte, NC 28232-2861, USA.

Archives of Family Medicine
|May 22, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liability issues with assistive technology projects [senior design].

IEEE pulse·2010
Same author

Chromium: friend or foe?

Archives of family medicine·1999
Same author

Apparent bigeminy and pulsus alternans in intermittent left bundle-branch block.

Clinical cardiology·1999
Same author

Alendronate treatment to prevent osteoporotic fractures.

Archives of family medicine·1998
Same author

Electrochemical response of CoCrMo to high-speed fracture of its metal oxide using an electrochemical scratch test method.

Journal of biomedical materials research·1997
Same author

Drug interactions: keeping it straight.

American family physician·1997
Same journal

Living in medicine: med school after 50 years plus 2 weeks

Archives of family medicine·2000
Same journal

Phytophotodermatitis: a sometimes difficult diagnosis.

Archives of family medicine·2000
Same journal

Case description of ascariasis.

Archives of family medicine·2000
Same journal

Microscopic polyangiitis in a pediatric patient.

Archives of family medicine·2000
Same journal

Advance care planning.

Archives of family medicine·2000
Same journal

Gaps in end-of-life care.

Archives of family medicine·2000
See all related articles

Mifepristone, an abortifacient, is highly effective (98%) when used early in pregnancy with misoprostol. While awaiting US approval, it shows promise for various other medical applications.

Area of Science:

  • Reproductive Medicine
  • Pharmacology

Background:

  • Mifepristone (RU 486) is an investigational drug in the US, with extensive European clinical experience.
  • It is primarily known for its abortifacient properties.

Purpose of the Study:

  • To review the efficacy and safety of mifepristone as an abortifacient.
  • To explore potential additional clinical applications of mifepristone.

Main Methods:

  • Review of retrospective studies and large, controlled clinical trials on mifepristone's efficacy.
  • Analysis of adverse effects and patient satisfaction surveys.

Main Results:

  • The regimen of 600 mg oral mifepristone followed by misoprostol is 98% effective for early pregnancy termination.

Related Experiment Videos

  • Painful contractions occur in up to 93% of women, often requiring analgesia.
  • High patient satisfaction rates were reported in large surveys.

    • Conclusions:

    • Mifepristone is a highly effective medical abortion option when used early in pregnancy.
    • Further research is investigating mifepristone for cervical ripening, labor induction, contraception, and cancer treatment.